Signal transduction in response to growth factors is a strictly controlled process with networks
of feedback systems, highly selective interactions and finely tuned on-and-off switches. In …

Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug
therapy to overcome the dismal prognosis of acute myelogenous leukemia (AML) patients …

Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS.
Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with …

The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth
factor receptor (EGFR/ErbB1), human EGFR 2 (HER2/ErbB2), ErbB3/HER3, and ErbB4/HER4. …

The KRAS oncogene is found in up to 30% of all human tumors. In 2009, RNAi experiments
revealed that lowering mRNA levels of a transcript encoding the serine/threonine kinase …

The ubiquitin E3 ligase Cbl has been shown to negatively regulate tyrosine kinase receptors,
including the stem cell factor receptor/c-Kit. Impaired recruitment of Cbl to c-Kit results in a …

Acute myeloid leukemia (AML) is a heterogeneous disease with variable patient responses
to therapy. Selinexor, an inhibitor of nuclear export, has shown promising clinical activity for …

Fms-like tyrosine kinase 3 (FLT3) plays an important role in hematopoietic differentiation,
and constitutively active FLT3 mutant proteins contribute to the development of acute myeloid …

Early signal relay steps upon ligand binding to the receptor tyrosine kinase Flt3 (ie, sites of
Flt3 autophosphorylation and subsequent docking partners) are mainly unresolved. By …

Targeted therapies have shown significant patient benefit in about 5–10% of solid tumors
that are addicted to a single oncogene. Here, we explore the idea of ligand addiction as a …